01/25/23 8:00 AMNasdaq : DNLI clinical trialDenali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by SanofiPartner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosis Denali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor program continues in a broad range ofRHEA-AIneutral
01/09/23 8:00 AMNasdaq : DNLI Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage DiseasesFour programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s disease Further validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV program, andRHEA-AIneutral
12/05/22 7:00 AMNasdaq : DNLI clinical trialDenali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialDNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALS Once-daily oral dosing with DNL343 for 28 days was generally well tolerated in participants with ALS The design phase for entry of DNL343 into a Phase 2/3RHEA-AIneutral
11/03/22 4:01 PMNasdaq : DNLI earningsDenali Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsDenali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial resultsRHEA-AIneutral
11/01/22 8:00 AMNasdaq : DNLI clinical trialDenali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRNInterim results from Part A in healthy volunteers demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593 Single doses of DNL593 were generally well tolerated Data support progression to enrolling participants with FTD-GRN in Part B of theRHEA-AInegative
10/24/22 4:30 PMNasdaq : DNLI offeringDenali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesDenali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in fullRHEA-AIneutral
10/19/22 9:19 PMNasdaq : DNLI offeringDenali Therapeutics Announces Pricing of $275 Million Public Offering of Common StockDenali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares are to be sold by DenaliRHEA-AIneutral
10/18/22 4:40 PMNasdaq : DNLI offeringDenali Therapeutics Announces Proposed Offering of Common StockDenali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant theRHEA-AIneutral
10/03/22 8:00 AMNasdaq : DNLI clinical trialBiogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic MutationsGlobal Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2 LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease Targeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s diseaseRHEA-AIneutral
08/31/22 8:00 AMNasdaq : DNLI clinical trialDenali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable central nervous system activity Safety profile, now with up to 85 weeks of dosing, continues to beRHEA-AIneutral